Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChloraPrep AQ is a brand-specific topical antiseptic formulation consisting of 2% w/v chlorhexidine gluconate (CHG) in an aqueous (water-based) vehicle. Developed by Becton, Dickinson and Company (BD) following the acquisition of CareFusion and C. R. Bard, this formulation is distinguished from the standard ChloraPrep product by the absence of isopropyl alcohol. It is specifically designed for preoperative skin preparation in clinical settings where alcohol-based solutions are contraindicated or undesirable, such as in neonatal care, on sensitive tissues, or near mucous membranes. The antimicrobial action of ChloraPrep AQ is derived from chlorhexidine's ability to bind to and disrupt microbial cell membranes, leading to the leakage of intracellular components and cell death. It provides broad-spectrum bactericidal activity and is noted for its persistence on the skin, maintaining antimicrobial efficacy for up to 48 hours after application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ChloraPrep AQ.